The decision to terminate the partnership follows the recent release of results from Advancis' Amoxicillin PULSYS Phase III clinical trials.
SPRING VALLEY, N.Y. – August 03, 2005 – Par Pharmaceutical Companies, Inc. today announced that it has terminated its partnership agreement with Advancis Pharmaceutical Corporation. The decision to terminate the partnership follows the recent release of results from Advancis' Amoxicillin PULSYS Phase III clinical trials. In both clinical trials, the Amoxicillin PULSYS product failed to achieve the desired microbiological and clinical endpoints. In 2004, Par entered into the agreement with Advancis to develop and market a novel formulation of the antibiotic amoxicillin.
Under the terms of the agreement, Par made quarterly payments to Advancis to fund the development of the Amoxicillin PULSYS product. Par's $4.75 million payment for the third quarter of 2005 fulfills Par's final obligation to Advancis. By terminating the partnership at this time, Par is no longer responsible for the fourth-quarter installment of $4.75 million, which would have represented Par's final payment to Advancis. If Advancis succeeds in developing and marketing any amoxicillin PULSYS product, Par will be reimbursed from the proceeds for up to half of its development expenses.
Par Pharmaceutical Companies, Inc. develops, manufactures and markets generic pharmaceuticals through its principal subsidiary, Par Pharmaceutical, Inc. The company is also developing an additional line of branded pharmaceutical products for specialty markets, the first of which is Megace(R) ES. Par currently manufactures, markets or licenses more than 90 prescription drugs. For press release and other company information, visit http://www.parpharm.com.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.